Journal Article

Management of systemic fungal infections: alternatives to itraconazole

R. Herbrecht, Y. Nivoix, C. Fohrer, S. Natarajan-Amé and V. Letscher-Bru

in Journal of Antimicrobial Chemotherapy

Volume 56, issue suppl_1, pages i39-i48
Published in print September 2005 | ISSN: 0305-7453
Published online September 2005 | e-ISSN: 1460-2091 | DOI:
Management of systemic fungal infections: alternatives to itraconazole

More Like This

Show all results sharing these subjects:

  • Medical Oncology
  • Critical Care


Show Summary Details


For many years, amphotericin B and flucytosine have been the only antifungal agents for invasive fungal infections. Amphotericin B was the standard of care for most of these infections. However, its use was often associated with low efficacy and poor tolerance. Fortunately, the antifungal armamentarium has increased during the past two decades with the addition of several new agents. In addition to itraconazole and fluconazole, lipid formulations of amphotericin B, voriconazole, caspofungin and micafungin have arrived on the market. Other agents are expected to be licensed shortly (anidulafungin, posaconazole). These various antifungal agents differ in their spectrum, pharmacokinetic profile, route of administration, efficacy in clinical trials, safety profile, drug–drug interactions and, importantly, their cost. There is no longer a unique standard agent for all or nearly all invasive fungal infections but a real choice among several agents. The characteristics of these new agents are reviewed to help clinicians in their decision to select an antifungal agent for their patients.

Keywords: antifungals; azoles; amphotericin B

Journal Article.  0 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.